{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:05:19Z","timestamp":1794668719766,"version":"4.9.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ygyno.2024.11.005","type":"journal-article","created":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T04:19:34Z","timestamp":1731730774000},"page":"80-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Prognostic and therapeutic implication of molecular classification including L1CAM expression in high-risk endometrial cancer"],"prefix":"10.1016","volume":"192","author":[{"given":"Andreas","family":"Kleppe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Lindemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanja","family":"Kildal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari Anne R.","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manohar","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ljiljana","family":"Vlatkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria X.","family":"Isaksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e5vard E.","family":"Danielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne A.","family":"Askautrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar B.","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2024.11.005_bb0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.ygyno.2024.11.005_bb0010","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Endometrial cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oaknin","year":"2022","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2024.11.005_bb0015","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.11.005_bb0020","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ygyno.2004.11.033","article-title":"Lymphvascular space involvement: an independent prognostic factor in endometrial cancer","volume":"96","author":"Briet","year":"2005","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.11.005_bb0025","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int. J. Gynecol. Obstet."},{"issue":"15","key":"10.1016\/j.ygyno.2024.11.005_bb0030","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/jnci\/djt144","article-title":"L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation","volume":"105","author":"Zeimet","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"issue":"15","key":"10.1016\/j.ygyno.2024.11.005_bb0035","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1016\/j.ejca.2014.07.014","article-title":"L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results","volume":"50","author":"Bosse","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2024.11.005_bb0040","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ygyno.2023.05.062","article-title":"Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer","volume":"174","author":"Kim","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"16","key":"10.1016\/j.ygyno.2024.11.005_bb0045","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved risk assessment by integrating molecular and Clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.ygyno.2024.11.005_bb0050","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41416-018-0187-6","article-title":"L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile","volume":"119","author":"Kommoss","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2024.11.005_bb0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2024.06.016","article-title":"The impact of estrogen receptor and L1 cell adhesion molecule expression on endometrial cancer outcome correlates with clinicopathological risk group and molecular subgroup","volume":"189","author":"Aro","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.11.005_bb0060","series-title":"Tumours of the Uterine Corpus. WHO Classification of Tumours Editorial Board. Female Genital Tumours","first-page":"246","volume":"Vol 4","author":"Matias-Guiu","year":"2020"},{"key":"10.1016\/j.ygyno.2024.11.005_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113584","article-title":"Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer","volume":"200","author":"Lindemann","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2024.11.005_bb0070","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdv484","article-title":"ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up","volume":"27","author":"Colombo","year":"2016","journal-title":"Ann. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.ygyno.2024.11.005_bb0075","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/PGP.0000000000000488","article-title":"Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility","volume":"38","author":"Kobel","year":"2019","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.11.005_bb0080","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/path.5372","article-title":"Interpretation of somatic POLE mutations in endometrial carcinoma","volume":"250","author":"Leon-Castillo","year":"2020","journal-title":"J. Pathol."},{"issue":"14","key":"10.1016\/j.ygyno.2024.11.005_bb0085","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/cncr.33516","article-title":"Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: an individual patient data meta-analysis","volume":"127","author":"McAlpine","year":"2021","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.ygyno.2024.11.005_bb0090","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/jnci\/djm024","article-title":"Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials","volume":"99","author":"Punt","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.ygyno.2024.11.005_bb0095","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","article-title":"Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium","volume":"105","author":"Pecorelli","year":"2009","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"2","key":"10.1016\/j.ygyno.2024.11.005_bb0100","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/modpathol.2015.147","article-title":"Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer","volume":"29","author":"Van Gool","year":"2016","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2024.11.005_bb0105","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1186\/s12885-016-2631-4","article-title":"L1CAM as a prognostic marker in stage I endometrial cancer: a validation study","volume":"16","author":"Smogeli","year":"2016","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2024.11.005_bb0110","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s41416-018-0310-8","article-title":"Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy","volume":"119","author":"Wortman","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.ygyno.2024.11.005_bb0115","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1097\/IGC.0b013e3182a5e77d","article-title":"Omitting adjuvant radiotherapy in endometrial cancer increases the rate of locoregional recurrences but has no effect on long-term survival: the Danish endometrial cancer study","volume":"23","author":"Ortoft","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2024.11.005_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061367","article-title":"Salvage radiation for pelvic relapse after surgically treated endometrial cancer","volume":"13","author":"Lindemann","year":"2021","journal-title":"Cancers"},{"issue":"29","key":"10.1016\/j.ygyno.2024.11.005_bb0125","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial Cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Leon-Castillo","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.11.005_bb0130","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/1078-0432.CCR-18-1443","article-title":"Frequent homologous recombination deficiency in high-grade endometrial carcinomas","volume":"25","author":"de Jonge","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.ygyno.2024.11.005_bb0135","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ygyno.2024.11.005_bb0140","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance Durvalumab with or without Olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.ygyno.2024.11.005_bb0145","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2024.11.005_bb0150","first-page":"109","article-title":"Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program","volume":"33","author":"Consortium RR","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"35","key":"10.1016\/j.ygyno.2024.11.005_bb0155","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1200\/JCO.22.02906","article-title":"Oral selinexor as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial Cancer","volume":"41","author":"Vergote","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.11.005_bb0160","doi-asserted-by":"crossref","unstructured":"Hogberg T, Signorelli M, de Oliveira CF et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur. J. Cancer 2010; 46 (13): 2422\u20132431.","DOI":"10.1016\/j.ejca.2010.06.002"},{"issue":"3","key":"10.1016\/j.ygyno.2024.11.005_bb0165","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial","volume":"19","author":"de Boer","year":"2018","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2024.11.005_bb0170","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ygyno.2022.02.024","article-title":"Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification","volume":"165","author":"Siegenthaler","year":"2022","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824012022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824012022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T01:17:10Z","timestamp":1738718230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824012022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":34,"alternative-id":["S0090825824012022"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.11.005","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic and therapeutic implication of molecular classification including L1CAM expression in high-risk endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}